The National Forum’s Value & Access Initiative Steering Committee and partners engaged in the value & access space provided consensus feedback on the Institute for Clinical and Economic Review (ICER)’s draft scope of the assessment of the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol™, Esperion Therapeutics, Inc.) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD.
